\BOOKMARK [0][-]{section*.4}{Glossary}{}% 1
\BOOKMARK [0][-]{section*.6}{Acronyms}{}% 2
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 101
\BOOKMARK [1][-]{section.4.1}{Synthetic Lethal Genes in Breast Cancer}{chapter.4}% 102
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic Lethal Pathways in Breast Cancer}{section.4.1}% 103
\BOOKMARK [2][-]{subsection.4.1.2}{Expression Profiles of Synthetic Lethal Partners}{section.4.1}% 104
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup Pathway Analysis}{subsection.4.1.2}% 105
\BOOKMARK [1][-]{section.4.2}{Comparing Synthetic Lethal Gene Candidates}{chapter.4}% 106
\BOOKMARK [2][-]{subsection.4.2.1}{Primary siRNA Screen Candidates}{section.4.2}% 107
\BOOKMARK [2][-]{subsection.4.2.2}{Comparison with Correlation}{section.4.2}% 108
\BOOKMARK [2][-]{subsection.4.2.3}{Comparison with Primary Screen Viability}{section.4.2}% 109
\BOOKMARK [2][-]{subsection.4.2.4}{Comparison with Secondary siRNA Screen Validation}{section.4.2}% 110
\BOOKMARK [2][-]{subsection.4.2.5}{Comparison to Primary Screen at Pathway Level}{section.4.2}% 111
\BOOKMARK [3][-]{subsubsection.4.2.5.1}{Resampling Genes for Pathway Enrichment}{subsection.4.2.5}% 112
\BOOKMARK [2][-]{subsection.4.2.6}{Integrating Synthetic Lethal Pathways and Screens}{section.4.2}% 113
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 114
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway Expression}{section.4.3}% 115
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic Mutation}{section.4.3}% 116
\BOOKMARK [2][-]{subsection.4.3.3}{Synthetic Lethal Pathway Metagenes}{section.4.3}% 117
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic Lethality in Breast Cancer}{section.4.3}% 118
\BOOKMARK [1][-]{section.4.4}{Replication in Stomach Cancer}{chapter.4}% 119
\BOOKMARK [1][-]{section.4.5}{Discussion}{chapter.4}% 120
\BOOKMARK [2][-]{subsection.4.5.1}{Strengths of the SLIPT Methodology}{section.4.5}% 121
\BOOKMARK [2][-]{subsection.4.5.2}{Synthetic Lethal Pathways for E-cadherin}{section.4.5}% 122
\BOOKMARK [2][-]{subsection.4.5.3}{Replication and Validation}{section.4.5}% 123
\BOOKMARK [3][-]{subsubsection.4.5.3.1}{Integration with siRNA Screening}{subsection.4.5.3}% 124
\BOOKMARK [3][-]{subsubsection.4.5.3.2}{Replication across Tissues}{subsection.4.5.3}% 125
\BOOKMARK [1][-]{section.4.6}{Summary}{chapter.4}% 126
\BOOKMARK [0][-]{section.4.6}{References}{}% 179
